Linus Health CDS Retrospective Validation Study
NCT05900310 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2023-06-12
Summary
This study is a retrospective validation study of deidentified Clinical Decision Support (CDS) recommendations generated by the Linus Health Core Cognitive Evaluation (CCE) for patients who have completed the CCE.
Site investigators consist of clinical experts including neurologists and geriatricians in the U.S. After signing the study agreements, the experts will receive batches of anonymized CCE outputs of patients and will rate the appropriateness of each CDS recommendation for each patient based on their review of the CCE results and their clinical judgment and expertise. The experts will also rate the clinical appropriateness of various parts of CDS pathways that form the LH CDS decision tree.
Conditions
- Cognitive Impairment
- Motor Disorders
- Dementia
Interventions
- DIAGNOSTIC_TEST
-
Core Cognitive Evaluation (CCE)
The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
Sponsors & Collaborators
-
Linus Health, Inc.
lead INDUSTRY
Principal Investigators
-
Ali Jannati, MD, PhD · Linus Health
Eligibility
- Min Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-06-30
- Primary Completion
- 2023-07-31
- Completion
- 2023-08-31
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Cognitive Neurology Unit Clinical Registry
NCT05925621 ·Status: RECRUITING
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338 ·Status: COMPLETED
-
Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease
NCT01055392 ·Status: UNKNOWN ·Phase: PHASE2
-
Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)
NCT03088956 ·Status: COMPLETED
-
ADRC Clinical Cohort (Alzheimer's Disease)
NCT06703541 ·Status: RECRUITING
-
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
NCT05225415 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
NCT06519357 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
NCT00230997 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
NCT02353598 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
NCT05104463 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02434666 ·Status: COMPLETED ·Phase: PHASE2
-
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
NCT01465360 ·Status: COMPLETED
-
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
NCT04735536 ·Status: COMPLETED ·Phase: PHASE2
-
Screening for Memory Studies
NCT01123018 ·Status: ACTIVE_NOT_RECRUITING
-
Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders
NCT00911690 ·Status: COMPLETED
-
MEMENTO-VAScular COmponents of Dementia
NCT02264899 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
NCT05189106 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
NCT02221661 ·Status: COMPLETED
-
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
NCT03522129 ·Status: COMPLETED ·Phase: PHASE1
-
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
NCT00551161 ·Status: COMPLETED ·Phase: PHASE4
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352 ·Status: RECRUITING ·Phase: PHASE3
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
NCT03802162 ·Status: COMPLETED ·Phase: PHASE1